Posted Jul. 25, 2012 at 6:27 a.m.

Premium Lock Merck licenses HIV compound from RTP-based Chimerix

Published: 2012-07-25 06:27:21
Updated: 2012-07-25 06:27:21

Print this blog post
Fighting HIV Merck will pay Chimerix $17.5 million on top of royalties on future sales and milestone payments of up to $151 million, according to both companies on Tuesday.

In exchange for exclusive worldwide license and funding the drug development and commercialization costs, Merck will pay Chimerix $17.5 million on top of royalties on future sales and milestone payments of up to $151 million....

Read More
Read More

WRAL Tech Wire any time: Twitter, Facebook

Copyright 2014 WRAL Tech Wire. All rights reserved.
Editor's Blog

Editor's Blog

The latest blog posts from our WRAL Tech Wire and WRAL editors. Read more articles…

Please Log In to add a comment.

Best of TechWire Insider

Techwire Inside Partners

OUR INSIDERS

Frank Vinluan
Life science
Vivek Wadhwa
Commentary
Dr. Mike Walden
Tech economy
Scroll